Nuformix PLC (LSE:NFX) (chairman Dr Alastair Riddell talks to Proactive London about the latest news about their data on NXP002.
NXP002 is their lead asset and a potential novel inhaled treatment for idiopathic pulmonary fibrosis.
The pharmaceutical development company is targeting unmet medical needs in fibrosis and oncology via drug repurposing. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.